ZHAOKE OPHTH has authorized the distribution and supply of an innovative drug for the treatment of presbyopia in Indonesia
ZHAOKE OPHTH has signed a distribution and supply agreement with Indonesian pharmaceutical company PTFerron, authorizing it to commercialize the innovative drug BRIMOCHOL PF for the treatment of presbyopia in Indonesia. The agreement grants PTFerron exclusive rights, including import, promotion, and sales of the product. ZHAOKE will receive an upfront payment and may obtain additional payments based on specific achievements. In addition, the developer of BRIMOCHOL PF, Tenpoint, received acceptance of its new drug application from the U.S. FDA in June
According to a report from Economic Information Daily on the 6th, ZHAOKE OPHTH (06622) announced that it has entered into a distribution and supply agreement with leading Indonesian pharmaceutical company PTFerron for the commercialization in Indonesia of the innovative drug BRIMOCHOL PF, licensed by Tenpoint, for the treatment of presbyopia. Under the terms, the company grants PTFerron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia, and the company will receive an upfront payment, with additional milestone payments available based on specific achievements. The company also mentioned that the developer of BRIMOCHOL PF, Tenpoint, has had the new drug application for the product accepted by the U.S. FDA in June of this year. (rh)
